We observed that H19 was highly expressed in Bcr-Abl-expressing primary CML cells derived from 4 patients, and imatinib treatment greatly decreased the expression of H19 in these cells but not in normal control cells. Loss of either Bcr-Abl expression or Abl kinase activity caused decrease of c-Myc levels with simultaneously reduced levels of H19. Furthermore, we demonstrated that depletion of c-Myc alone in K562 cells significantly decreased the level of H19, suggesting that H19 is expressed in a c-Myc dependent manner in K562 leukemic cells.